Epstein-Barr Virus Reactivation Correlates with Worse Outcomes for Patients Exposed to Hepatitis B Virus After Haploidentical Hematopoietic Stem Cell Transplantation

Overview

Journal Ann Hematol

Specialty Hematology

Date 2023 Oct 13

PMID 37831153

Authors

Jiajia Hu

Jie Zhao

Chunyan Wang

Mei Jia

Ming Su

Shanshan Li

Affiliations

Soon will be listed here.

Abstract

Hepatitis B virus (HBV)has a high, chronic infection rate in Asian populations, but only few studies have analyzed the effect of Epstein-Barr virus (EBV) or Cytomegalovirus (CMV) reactivation in patients exposed to HBV after haploidentical hematopoietic stem cell transplantation (haplo-HSCT). This study aimed to assess the clinical outcomes of these patients. We conducted a retrospective research including 61 patients exposed to HBV after undergoing haplo-HSCT. The patients were classified into two groups: the CMV reactivation group and no CMV reactivation group. The results were compared between the two groups using the K-W test for continuous variables, Pearson's chi-square test for categorical variables, Kaplan-Meier curves to estimate overall survival (OS) and leukemia-free survival (LFS), and a Cox proportional hazards model to analyze multivariable influences. The 3-year cumulative HBV reactivation rate was 8.2%. The median duration of HBV reactivation was 16 months (16-22 months) after haplo-HSCT. The CMV reactivation group had a higher cumulative incidence of HBV reactivation than the group without CMV reactivation. The EBV reactivation was substantially higher in the CMV reactivation group compared to that in the no CMV reactivation group (37.0% vs.5.9% respectively; P = 0.002). Furthermore, EBV reactivation was a risk factor for 1-year LFS and 1-year OS. Based on our data, EBV reactivation was related to worse outcomes in patients exposed to HBV after haplo-HSCT, whereas CMV reactivation was not.

References

Fung S, Choi H, Gehring A, Janssen H . Getting to HBV cure: The promising paths forward. Hepatology. 2022; 76(1):233-250. DOI: 10.1002/hep.32314. View

Xu X, Wu C, Lou Z, Peng C, Jiang L, Wu T . Changing incidence of hepatitis B and persistent infection risk in adults: a population-based follow-up study from 2011 in China. BMC Public Health. 2023; 23(1):256. PMC: 9901124. DOI: 10.1186/s12889-023-15130-y. View

Yuen M, Chen D, Dusheiko G, Janssen H, Lau D, Locarnini S . Hepatitis B virus infection. Nat Rev Dis Primers. 2018; 4:18035. DOI: 10.1038/nrdp.2018.35. View

Shi Y, Zheng M . Hepatitis B virus persistence and reactivation. BMJ. 2020; 370:m2200. DOI: 10.1136/bmj.m2200. View

Lopez-Fernandez T, Vadillo I, Lopez de la Guia A, Barbier K . Cardiovascular Issues in Hematopoietic Stem Cell Transplantation (HSCT). Curr Treat Options Oncol. 2021; 22(6):51. DOI: 10.1007/s11864-021-00850-3. View

Xu L, Wu D, Han M, Huang H, Liu Q, Liu D . A review of hematopoietic cell transplantation in China: data and trends during 2008-2016. Bone Marrow Transplant. 2017; 52(11):1512-1518. DOI: 10.1038/bmt.2017.59. View

Nagler A, Labopin M, Houhou M, Aljurf M, Mousavi A, Hamladji R . Outcome of haploidentical versus matched sibling donors in hematopoietic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow.... J Hematol Oncol. 2021; 14(1):53. PMC: 8017786. DOI: 10.1186/s13045-021-01065-7. View

Wang Y, Wu D, Liu Q, Xu L, Liu K, Zhang X . Low-dose post-transplant cyclophosphamide and anti-thymocyte globulin as an effective strategy for GVHD prevention in haploidentical patients. J Hematol Oncol. 2019; 12(1):88. PMC: 6724335. DOI: 10.1186/s13045-019-0781-y. View

Stern A, Su Y, Dumke H, Fang J, Tamari R, Jakubowski A . Cytomegalovirus Viral Load Kinetics Predict Cytomegalovirus End-Organ Disease and Mortality After Hematopoietic Cell Transplant. J Infect Dis. 2021; 224(4):620-631. PMC: 8366442. DOI: 10.1093/infdis/jiab212. View

10.

Wu Y, Huang H, Luo Y . Management of Hepatitis B Virus in Allogeneic Hematopoietic Stem Cell Transplantation. Front Immunol. 2021; 11:610500. PMC: 7890023. DOI: 10.3389/fimmu.2020.610500. View

11.

Li S, Zhang N, Jia M, Su M . Association Between Cytomegalovirus and Epstein-Barr Virus Co-Reactivation and Hematopoietic Stem Cell Transplantation. Front Cell Infect Microbiol. 2022; 12:818167. PMC: 8992791. DOI: 10.3389/fcimb.2022.818167. View

12.

Xu L, Chen H, Chen J, Han M, Huang H, Lai Y . The consensus on indications, conditioning regimen, and donor selection of allogeneic hematopoietic cell transplantation for hematological diseases in China-recommendations from the Chinese Society of Hematology. J Hematol Oncol. 2018; 11(1):33. PMC: 5833104. DOI: 10.1186/s13045-018-0564-x. View

13.

Wang Y, Fu H, Liu D, Xu L, Zhang X, Chang Y . Influence of two different doses of antithymocyte globulin in patients with standard-risk disease following haploidentical transplantation: a randomized trial. Bone Marrow Transplant. 2013; 49(3):426-33. DOI: 10.1038/bmt.2013.191. View

14.

Demirtas D, Cagdas D, Turul Ozgur T, Kuskonmaz B, Uckan Cetinkaya D, Sanal O . Long Term Follow-Up of the Patients with Severe Combined Immunodeficiency After Hematopoietic Stem Cell Transplantation: A Single-Center Study. Immunol Invest. 2021; 51(4):739-747. DOI: 10.1080/08820139.2020.1869776. View

15.

Huang X, Liu D, Liu K, Xu L, Chen H, Han W . Treatment of acute leukemia with unmanipulated HLA-mismatched/haploidentical blood and bone marrow transplantation. Biol Blood Marrow Transplant. 2009; 15(2):257-65. DOI: 10.1016/j.bbmt.2008.11.025. View

16.

Terrault N, Lok A, McMahon B, Chang K, Hwang J, Jonas M . Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018; 67(4):1560-1599. PMC: 5975958. DOI: 10.1002/hep.29800. View

17.

Yang Y, Huang A, Zhao Y . Spontaneous loss of chronic HBV infection markers in treatment-naïve children: a systematic review and pooled meta-analyses. Expert Rev Anti Infect Ther. 2020; 19(5):649-660. DOI: 10.1080/14787210.2021.1845652. View

18.

Yu S, Huang F, Wang Y, Xu Y, Yang T, Fan Z . Haploidentical transplantation might have superior graft-versus-leukemia effect than HLA-matched sibling transplantation for high-risk acute myeloid leukemia in first complete remission: a prospective multicentre cohort study. Leukemia. 2019; 34(5):1433-1443. DOI: 10.1038/s41375-019-0686-3. View

19.

Lu Y, Zhao Y, Zhang J, Xiong M, Cao X, Liu D . Comparable outcomes among unmanipulated haploidentical, matched unrelated, and matched sibling donors in BU-based myeloablative hematopoietic stem cell transplantation for intermediate and adverse risk acute myeloid leukemia in complete remission: a.... Ann Hematol. 2020; 100(6):1579-1591. DOI: 10.1007/s00277-020-04355-1. View

20.

Shih C, Chen W . Prevention of hepatitis B reactivation in patients requiring chemotherapy and immunosuppressive therapy. World J Clin Cases. 2021; 9(21):5769-5781. PMC: 8316946. DOI: 10.12998/wjcc.v9.i21.5769. View